Improving glioma diagnosis and treatment through molecular analysis
Official title: A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
Run by University of Birmingham · NCT04274283 · Data updated 2026-11-12
This study is trying to improve how gliomas are diagnosed and treated by looking at the genetic changes in tumors to find better, personalized therapies for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Birmingham Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 14 sites (Birmingham and 13 other locations) |
| Status | Recruiting |
| Started | November 24, 2020 |
| Main results expected | February 2027 |
| Study ends | February 2028 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT04274283 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with newly diagnosed or progressing WHO Grade 2-4 gliomas who are suitable for surgical procedures that allow for tumor and blood sample collection.
✕Probably not a fit
Patients with primary spinal cord tumors or those undergoing active treatment for other malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Tessa Jowell BRAIN MATRIX - Platform Study aims to enhance the precision of glioma diagnosis by establishing a network of clinical hubs across the UK that specialize in brain tumor management. This initiative focuses on developing the infrastructure necessary for rapid and accurate molecular diagnosis of gliomas, which are challenging to treat due to their complex nature. By analyzing the genetic changes in tumors, the study seeks to identify targeted therapies that could improve patient outcomes. Ultimately, this platform will facilitate the introduction of clinical trials for tailored treatments based on individual tumor profiles.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and personalized treatment options for patients with gliomas, potentially improving survival rates and quality of life.
How similar studies have gone: Other studies focusing on molecular diagnostics and targeted therapies for gliomas have shown promise, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis). * Valid written informed consent for the study. Exclusion Criteria: * Primary spinal cord tumours * Active treatment of other malignancy * Contraindication to MRI * Patients without standard of care imaging available
Where it's running
-
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom Recruiting -
Velindre Cancer Centre, Velindre University NHS Trust
Cardiff, United Kingdom Recruiting -
St James's University Hospital, Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom Recruiting -
The Walton Centre, The Walton Centre NHS Foundation Trust
Liverpool, United Kingdom Recruiting -
King's College Hospital, King's College Hospital NHS Foundation Trust
London, United Kingdom Recruiting -
Charing Cross Hospital, Imperial College Healthcare NHS Trust
London, United Kingdom Recruiting
Show 8 more locations
-
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, United Kingdom Recruiting -
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom Recruiting -
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom Recruiting -
Queen's Medical Centre, Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom Recruiting -
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom Recruiting -
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom Terminated -
NHS Lothian
Edinburgh, United Kingdom Active not recruiting -
Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board
Glasgow, United Kingdom Active not recruiting
Study contacts
- Principal investigator: Colin Watts — Unviersity of Birmingham
- Study coordinator: Rhys Mant
- Email: brainmatrix@trials.bham.ac.uk
- Phone: 0121 414 6788
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.